Gilead invested $5.1 billion to deepen its collaboration with Galapagos, comprising a $3.95 billion upfront payment and a $1.1 billion equity investment (raising its stake from 12.3% to 22%). The 10-year agreement gave Gilead access to six clinical-phase assets, 20 preclinical programs, and option rights on all future Galapagos pipeline programs. For filgotinib specifically, Galapagos gained greater involvement in global strategy and European commercialization, with costs shared 50:50 (replacing the prior 80:20 split).